Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0WQ9X
|
|||
| Drug Name |
PMID30107136-Compound-Example1
|
|||
| Drug Type |
Small molecule immunotherapy
|
|||
| Indication | Hepatitis [ICD-11: DB97.Z] | Patented | [1] | |
| Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 42] | Patented | [1] | ||
| Infectious disease [ICD-11: 1A00-CA43.1; ICD-10: A00-B99; ICD-9: 001-139] | Patented | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Patented | [1] | ||
| Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H29N3O3
|
|||
| Canonical SMILES |
CC1=C(C=CC=C1C2=CC=CC=C2)COC3=NC(=C(C=C3)CNCCNC(=O)C)OC
|
|||
| InChI |
1S/C25H29N3O3/c1-18-22(10-7-11-23(18)20-8-5-4-6-9-20)17-31-24-13-12-21(25(28-24)30-3)16-26-14-15-27-19(2)29/h4-13,26H,14-17H2,1-3H3,(H,27,29)
|
|||
| InChIKey |
JEDPSOYOYVELLZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Programmed cell death 1 ligand 1 (PD-L1) | Target's Patent Info | [1] | |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.